Medine.co.uk

Nobilis Paramyxo P201

Revised: February 2016

Amended pages

SUMMARY OF PRODUCT CHARACTERISTICS


1. NAME OF THE VETERINARY MEDICINAL PRODUCT


Nobilis Paramyxo P201


2. QUALITATIVE AND QUANTITATIVE COMPOSITION


Per dose of 0.25 ml:


Active substance:


Pigeon Paramyxo virus-1 (PPMV-1) antigen strain P201, inactivated : inducing 6.8 log2HI*and 10.2 log2HI units in chickens


*Haemagglutination Inhibition


Excipient:

Liquid paraffin 138 mg


For a list of excipients, see section 6.1


3. PHARMACEUTICAL FORM


Emulsion for injection


4. CLINICAL PARTICULARS


4.1 Target species


Pigeons


4.2 Indications for use, specifying the target species


Active immunisation of pigeons to reduce clinical signs caused by virulent PPMV-1 infection. The vaccine has been shown to significantly reduce virus excretion after challenge.

Onset of immunity: 4 weeks after primary vaccination.

A duration of immunity of 1 year has been demonstrated.


4.3 Contraindications


Do not use in sick animals.


4.4 Special warnings


None


4.5 Special precautions for use


Special precautions for use in animals


None


Special precautions to be taken by the person administering the veterinary medicinal product to animals


To the user:

This product contains mineral oil. Accidental injection/self injection could result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.

If you are accidentally injected with the product, seek prompt medical advice even if only a very small amount is injected and take the package insert with you.

If pain persists for more than 12 hours after medical examination, seek medical advice again.


To the physician:

This product contains mineral oil. Even if small amounts have been injected, accidental injection with this product may cause intensive swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of a finger pulp or tendon.


4.6 Adverse reactions (frequency and seriousness)


No clinical signs have been observed after vaccination.


4.7 Use during lay


Vaccination within 4 weeks of the start of the breeding season is not recommended. No information is available on the safety of this product during the reproduction period.


4.8 Interaction with other medicinal products and other forms of interaction


No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.



4.9 Amounts to be administered and administration route


Allow the vaccine to reach ambient temperature (15-25C) before use. Shake well before use. Use sterile syringes and needles.


Each animal should be given 0.25 ml of vaccine by subcutaneous injection into the lower back area of the neck.


Birds can be vaccinated from five weeks of age.


Annual revaccination is recommended.


4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary


Following the administration of a double dose of vaccine no side effects other than those described in section 4.6 have been observed.


4.11 Withdrawal period


Zero days


5. IMMUNOLOGICAL PROPERTIES


To stimulate active immunity against PPMV-1 infection in pigeons.

ATC vet.Code: QI01EA01


6. PHARMACEUTICAL PARTICULARS


6.1 List of excipients


Polysorbat 80, Sorbitan mono-oleate, Glycine, Water for injection.


6.2 Incompatibilities


Do not mix with any other vaccine/immunological products.


6.3 Shelf life


Shelf-life of the veterinary medicinal product as packaged for sale: 2 years.

Shelf life after first opening: immediate use after opening.


6.4 Special precautions for storage


Store in a refrigerator (2°C - 8°C). Do not freeze.



6.5 Nature and composition of immediate packaging


Multidose container of 20, 50, and 250 ml of Polyethylene terephthalate (PET) and closed with a nitryl rubber stopper and sealed with a coded aluminium cap.


Not all pack sizes may be marketed.


6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products


Any unused product or waste material should be disposed of in accordance with national requirements.


7. MARKETING AUTHORISATION HOLDER


Intervet UK Ltd.

Walton Manor

Walton

Milton Keynes

Buckinghamshire

MK7 7AJ


8. Marketing authorisation number


Vm 01708/4489


9. renewal of the authorisation


05 April 2010


10. Date of revision of the text


February 2016


Prohibition of sale, supply and/or use


National and EU legislation on PMV-1 infections (PPMV-1, Newcastle Disease, etc.) should be considered with regard to the use of this product, as vaccination of certain subclasses of pigeons may be prohibited in some countries.


Approved: 12 February 2016

Page 4 of 4